Prediction of pathological stage in patients with clinical stage T1c prostate cancer: The new challenge

被引:23
|
作者
Veltri, RW
Miller, MC
Mangold, LA
O'Dowd, GJ
Epstein, JI
Partin, AW
机构
[1] Johns Hopkins Med Inst, Brady Urol Inst, Baltimore, MD 21205 USA
[2] Immunicon Corp, Huntingdon, PA USA
[3] UroCor Inc, Oklahoma City, OK USA
来源
JOURNAL OF UROLOGY | 2002年 / 168卷 / 01期
关键词
prostate; prostatic neoplasms; prostate-specific antigen; tumor markers; biological; neoplasm staging;
D O I
10.1016/S0022-5347(05)64839-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We developed an algorithm for predicting the likelihood of organ confined disease in patients with clinical stage T1c prostate cancer using biopsy pathology, computer assisted image analysis and serum prostate specific antigen (PSA). Materials and Methods: Of the 557 consecutive men enrolled in this study between October 1998 and January 2000 scheduled for radical prostatectomy at a single institution 386 (69%) presented with clinical stage T1c disease. Study exclusion criteria included neoadjuvant hormonal treatment with luteinizing hormone-releasing hormone, antiandrogen or 5alpha-reductase inhibitors. Preoperative serum, biopsy histology slides, clinical demographic information, prostatectomy pathology and prostate weight data were obtained. Biomarkers assessed included total PSA, complexed PSA, free PSA, the free-to-total PSA ratio, quantitative nuclear grade determined by image analysis, complexed PSA density, and biopsy Gleason grade and score. To determine patient specific quantitative nuclear grade values, images from approximately 125 cancer nuclei were captured per patient from the area of the biopsy section with the highest Gleason score. The variance in 60 nuclear size, shape and chromatin texture descriptors was calculated for each gallery of nuclei. Logistic regression was done to determine the most accurate combination of variables for predicting organ confined prostate cancer. Results: Complete results and data were available on 255 of the 386 men (66%) with an average age plus or minus standard deviation of 58.8 +/- 6 years who had stage T1c disease, including 49 (19%) with pathologically nonorgan confined disease. Logistic regression analysis revealed that quantitative nuclear grade, biopsy Gleason score, total PSA, the calculated free-to-total PSA ratio, complexed PSA and complexed PSA density were univariately significant for predicting organ confined disease (p < 0.05). On backward stepwise logistic regression only quantitative nuclear grade, complexed PSA density and Gleason score remained in a model yielding an area under the receiver operating characteristics curve of 82.4%. Conclusions: The quantitative nuclear grade biomarker was the strongest independent predictor of pathological stage in men with clinical stage T1c prostate cancer when combined with biopsy Gleason score and complexed PSA density data.
引用
收藏
页码:100 / 104
页数:5
相关论文
共 50 条
  • [41] INCIDENCE OF IMAGING ABNORMALITIES IN PATIENTS WITH NONPALPABLE CARCINOMA OF THE PROSTATE - IF YOU CAN SEE IT, IS IT STAGE T1C
    WERNERWASIK, M
    WHITTINGTON, R
    MALKOWICZ, SB
    CORN, BW
    ARGER, PH
    REISINGER, SA
    RADIOLOGY, 1995, 197 : 330 - 330
  • [42] Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings
    Epstein, JI
    Chan, DW
    Sokoll, LJ
    Walsh, PC
    Cox, JL
    Rittenhouse, H
    Wolfert, R
    Carter, HB
    JOURNAL OF UROLOGY, 1998, 160 (06): : 2407 - 2411
  • [43] Prostate cancer: Are clinical stages t1c and t2 similar?
    Billis, A
    Magna, LA
    Watanabe, IC
    Costa, MV
    Telles, GHQ
    Ferreira, U
    LABORATORY INVESTIGATION, 2005, 85 : 130A - 130A
  • [44] Prostate cancer: Are clinical stages T1c and T2 similar?
    Billis, A
    Magna, LA
    Watanabe, IC
    Costa, MV
    Telles, GHQ
    Ferreira, U
    MODERN PATHOLOGY, 2005, 18 : 130A - 130A
  • [45] Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade
    Haese, A
    Vaisanen, V
    Lilja, H
    Kattan, MW
    Rittenhouse, HG
    Pettersson, K
    Chan, DW
    Huland, H
    Sokoll, LJ
    Partin, AW
    JOURNAL OF UROLOGY, 2005, 173 (03): : 752 - 756
  • [46] PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER
    EPSTEIN, JI
    WALSH, PC
    CARMICHAEL, M
    BRENDLER, CB
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (05): : 368 - 374
  • [47] CLINICAL STAGE B(0) OR T1C PROSTATE-CANCER - NONPALPABLE DISEASE IDENTIFIED BY ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN CONCENTRATION
    STORMONT, TJ
    FARROW, GM
    MYERS, RP
    BLUTE, ML
    ZINCKE, H
    WILSON, TM
    OESTERLING, JE
    UROLOGY, 1993, 41 (01) : 3 - 8
  • [48] Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model
    Cosma, Georgina
    Acampora, Giovanni
    Brown, David
    Rees, Robert C.
    Khan, Masood
    Pockley, A. Graham
    PLOS ONE, 2016, 11 (06):
  • [49] Change in prostate cancer grade over time in men followed expectantly for stage T1c disease - Comment
    Jarrard, David F.
    JOURNAL OF UROLOGY, 2008, 179 (03): : 904 - 905
  • [50] Free-to-total prostate specific antigen ratio as a single test for detection of significant stage T1c prostate cancer
    Elgamal, AAA
    Cornillie, FJ
    VanPoppel, HP
    VandeVoorde, WM
    McCabe, R
    Baert, LV
    JOURNAL OF UROLOGY, 1996, 156 (03): : 1042 - 1047